Home - Dan Marold

Evolution in Motion

The Chill6™ Standard

Refined through experience. Evolution through time. A continued commitment to building better.

Dan Marold & Chill6 Have Been Featured In

The Mind Behind Chill6™

My name is Dan Marold, also known as Daniel Marold, and I am the mind behind Chill6™. This page reflects the development of the product, the evolution of its formulation over time, and the continued focus on refining and improving the brand.

Chill6™ has been shaped through years of development, real-world use, and ongoing iteration, influenced by experience and evolving standards within the dietary supplement industry. This page provides context on that progression and the direction moving forward.

What Happened with Chill6™

The original Chill6™ journey began in 2015, launched during a time when the FDA’s stance on phenibut was permissive within the dietary supplement industry. For four years, we operated successfully under those standards. However, in 2019, the regulatory landscape shifted dramatically.

When the FDA issued new guidance requiring updates to product labeling, we implemented those changes immediately to stay in alignment with federal expectations. As the government’s position continued to evolve, Chill6™ eventually became subject to an injunction that required the discontinuation of the original formulation.

We learned quickly that you “can’t fight city hall.” In a complete commitment to compliance and the safety of our community, we proactively withdrew the original product from the market and destroyed all remaining inventory. It is important to note that no criminal or civil charges were ever brought; the matter was strictly a transition of formulation in response to shifting federal policy.

Even today, the Centers for Disease Control and Prevention (CDC) acknowledges that phenibut remains a “legal, uncontrolled substance” (Source: CDC.gov, 2026). However, we have chosen a higher path.

Our return is built on a foundation of integrity: new ingredients, precision dosing, and rigorous clinical review. By utilizing labeling that avoids disease claims and prioritizes transparency, we aren’t just following the rules—we are protecting you and the heart of the brand you trust.

The Standards Behind Chill6™

Built with responsibility. Acted with integrity. Evolved without exception.

Every Ingredient Has a Purpose

Each component in Chill6™ is selected with clear intent and a defined role within the formulation, creating a structured and balanced product design.

Built Through Structured Formulation

Chill6™ is developed through a controlled formulation process focused on consistency, precision, and long-term stability across every batch.

Produced in Controlled Facilities

Manufacturing takes place in FDA-registered, cGMP-compliant facilities with standardized processes, documented procedures, and consistent quality control.

Evolved Through Real-World Use

Chill6™ has been shaped over time through real-world use, ongoing evaluation, and continuous refinement of its formulation structure.

Always Moving Forward

The commitment behind Chill6™ is ongoing improvement—refining and strengthening the formulation as standards and expectations continue to evolve.

Evolution in Motion

Evolution in motion is continuous responsibility—not a single moment, but an ongoing standard for how things are built, refined, and carried forward.

Every decision is guided by responsible business practices and long-term accountability.

Every formulation is built with consistency, transparency, and structured oversight from development through production.

Every product reflects a commitment to the people who use Chill6™ and the community that has supported its evolution.

This is not a statement of perfection, it is a commitment to continuous improvement. Chill6™ reflects the experience of building, learning, and refining over time, and the responsibility that comes with creating something used by thousands of people. That responsibility continues to guide every decision moving forward.

A New Era for Chill6™

Chill6™ has been fully reimagined with a renewed focus on modern formulation standards, ingredient structure, and manufacturing precision. This evolution reflects years of real-world use, continued refinement, and a structured approach to aligning the product with current dietary supplement expectations.

Reformulated Without Phenibut

Phenibut was part of the original Chill6™ formulation when it was developed in 2015, at a time when it was used in certain dietary supplement products in the U.S. market. Several years later, its classification within the dietary supplement category changed, and it is no longer considered an acceptable ingredient for use in supplement formulations.

Chill6™ has since been fully reformulated using a new system of carefully selected ingredients designed to preserve the original functional intent of the product through a more modern and structured formulation approach.

Precision Manufacturing Standards

Chill6™ is manufactured in FDA-registered, cGMP-compliant facilities that operate under strict production standards. These facilities follow documented procedures, controlled processes, and quality assurance protocols designed to ensure consistency across every stage of production, from raw material handling to final packaging.

Reviewed by Formulation Standards

The Chill6™ formulation has been reviewed with attention to ingredient balance, system design, and structural consistency. This process evaluates how each component functions within the overall blend, ensuring the formula operates as a unified system rather than a collection of individual ingredients.

Ingredient Clarity by Design

Each ingredient in Chill6™ is selected with clear intent and a defined role within the overall formulation. This creates a structured and transparent composition where every element contributes purposefully to the overall design, consistency, and functional architecture of the product.

The new Chill6™ is not simply a product, it is the result of disciplined refinement, sustained development, and experience earned over time. It reflects a continued commitment to building with clarity, structure, and purpose.

Forward in Motion

Search “Dan Marold,” “Daniel Marold,” or “Dan Marold Chill6™” and you will find a progression defined by building, refinement, and continuous improvement of the Chill6™ formulation.

Each stage of development has informed the next, leading to a more structured, intentional, and modern approach to product creation.

This is not the end of the story, but the beginning of a new chapter for Chill6™—focused on precision, consistency, and forward momentum in every aspect of the brand and formulation.

Built Through Iteration: Each version of Chill6™ has been shaped by real-world use, ongoing refinement, and a commitment to improving the formulation over time.

Structured for Consistency: The current formulation reflects a more disciplined and structured approach to ingredient selection, balance, and overall system design.

Guided by Experience: Years of development and application have informed a more precise and intentional direction for how Chill6™ is formulated and produced.

Aligned with Modern Standards: Chill6™ continues to evolve in step with current expectations for ingredient structure, manufacturing practices, and product consistency.

Focused on What Comes Next: The direction forward is clear, continue refining, strengthening, and improving Chill6™ through a disciplined and forward-moving approach.

Statement from Daniel Marold

The Chill6™ Regulatory Record: A Legacy of Compliance and Evolution

At Chill6™, we believe that transparency is the foundation of trust. For those seeking a clear account of our transition, our history is an open book.

Originally developed in 2015, the first iteration of Chill6™ included phenibut—an ingredient that was widely utilized in dietary supplements at the time. When federal guidance began to shift in 2019, we proactively updated our labeling to meet the FDA’s evolving standards. As the regulatory landscape reached its final pivot, Chill6™ was subject to an injunction requiring the discontinuation of the original formula.

We chose to handle this transition with total integrity: all remaining inventory was destroyed, and the original product was fully withdrawn from the market. It is a matter of public record that no criminal or civil charges were brought; the outcome was focused solely on the transition of ingredients to meet new federal expectations.

Today, while the CDC acknowledges that phenibut remains a ‘legal, uncontrolled substance’ (Source: CDC.gov, 2026), we have moved forward. The new Chill6™ is a testament to that evolution—fully reformulated, precision-dosed, and built to exceed current manufacturing standards. We didn’t just return; we returned better.

Read Now

Learn More!

Read Now

Official Clarification Regarding Regulatory Documentation

The involvement of the U.S. Department of Justice (DOJ) was a procedural necessity, functioning as the formal mechanism required to document and finalize the injunction regarding our original formulation.

It is important to clarify that this process was administrative. At no point were criminal charges filed or civil penalties pursued. The scope of the DOJ’s role was strictly limited to formalizing the discontinuation of the original formulation containing phenibut.

In matters involving federal agencies, official documentation often utilizes standardized language that may not fully reflect the complexities of the situation or the perspectives of the business owners involved. While the characterizations in these public filings often differed from the position held by Daniel Marold, the decision was made to comply with the injunction and conclude the proceedings. This choice allowed Chill6™ to move forward without the burden of prolonged legal escalation, focusing our resources entirely on the safety and integrity of our next generation of products.

Read Now

Learn More!

Read Now

Read The Chill6 Trilogies

Chill6 Trilogies is a comprehensive, fact-based blog series created to document the full regulatory journey of Chill6, including the FDA warning letter, the DOJ civil action, and the permanent injunction that followed. This series breaks down each action in plain language, explains what the agencies did and did not allege, and clarifies how regulatory classification, ingredient status, and marketing language shaped the outcome. Most importantly, Chill6 Trilogies outlines the concrete steps taken since those actions, including halting non-compliant distribution, permanently removing phenibut, rebuilding the product with compliant ingredients, restructuring marketing practices, and implementing professional oversight to ensure long-term regulatory alignment. The purpose of this series is transparency, education, and accountability, providing accurate information about Chill6’s past, present, and future in one centralized resource.